NIAID awards VaxInnate a $2.2M grant to develop dengue vaccine

04/5/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded VaxInnate a three-year grant worth $2.2 million to develop a recombinant tetravalent dengue vaccine using the company's Toll-like receptor (TLR) platform. The TLR technology is intended to increase vaccine efficacy and immunogenicity.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA